Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL115045 | 0.81 | CYP11B1 (0.30) | CYP11B1CYP11B2 | |
| SCHEMBL7996511 | 0.79 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL335735 | 0.79 | KIF11 (0.31) | RXRAGRIN1GRIN2BHSD17B10KIF11 | |
| SCHEMBL8490451 | 0.75 | CYP2A6 (0.38) | HSD17B10RECQLCYP11B1CYP11B2 | |
| SCHEMBL487778 | 0.75 | CYP11B1 (0.50) | RECQLCYP11B1CYP11B2 | |
| SCHEMBL2060171 | 0.75 | HTT (0.54) | HSD17B10ALOX15TSHRRECQL | |
| SCHEMBL335179 | 0.75 | HSD17B10 (0.37) | HSD17B10ALOX15TSHRRECQLACHE | |
| SCHEMBL29879799 | 0.75 | HTT (0.54) | HSD17B10ALOX15TSHRRECQL | |
| SCHEMBL22031726 | 0.75 | RXRA (0.35) | RXRAGRIN1GRIN2BRECQLCYP11B1 | |
| SCHEMBL2714804 | 0.73 | PTGS2 (0.36) | RXRAGRIN1GRIN2BHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448921-A1 | ARYL INDOLE DERIVATIVES | MSD K.K. (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20120022078-A1 | ARYL INDOLE DERIVATIVES | MSD K.K. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120022078-A1 | ARYL INDOLE DERIVATIVES | MSD K.K. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120022078-A1 | ARYL INDOLE DERIVATIVES | MSD K.K. (JP) | 2012-01-26 | — | — | US | disclosed |
| WO-2010117085-A1 | ARYL INDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010117085-A1 | ARYL INDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022078-A1 | ARYL INDOLE DERIVATIVES | IDO1, NAT1, IDO2 | RXRA 1681/4885GRIN1 1670/4885GRIN2B 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.